Ceralasertib

Small molecule

Phase 3topline reported

Evidence outlook · registrational

Topline reported 2025-12-22

Its supporting mid-stage studies have completed. The sponsor reported topline results on 2025-12-22 (LATIFY Phase III did not meet primary endpoint of overall survival). The announcement is listed under Regulatory events.

Development in Non-Small Cell Lung Cancer stopped (2025-12-22) as a strategic decision by the sponsor. Development continues in another indication. Source

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
Phase 2 (30)
Other / comorbidity
NCT06769126 · SWOG Cancer Research Network
2025-11-06 – 2029-12-31 · Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
What this study did
NCT05582538 · IFOM ETS - The AIRC Institute of Molecular Oncology
2022-12-15 – 2029-12 · Triple Negative Breast Cancer Metastatic
What this study did
NCT06680050 · Mario Negri Institute for Pharmacological Research
2025-08-07 – 2029-01 · Non Small Cell Lung Cancer NSCLC
What this study did
NCT03787680 · University of Michigan Rogel Cancer Center
2019-10-31 – 2028-08 · Prostate Cancer
What this study did
NCT03682289 · Rahul Aggarwal
2019-01-17 – 2028-03-31 · Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT04090567 · M.D. Anderson Cancer Center
2020-07-28 – 2027-12-31 · Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03780608 · Samsung Medical Center
2019-07-30 – 2027-12-01 · Gastric Adenocarcinoma, Malignant Melanoma
What this study did
NCT03878095 · National Cancer Institute (NCI)
2020-01-30 – 2027-07-10 · Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm
What this study did
NCT04699838 · Muhammad Furqan
2021-04-20 – 2027-04 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT03579316 · M.D. Anderson Cancer Center
2018-12-07 – 2026-12-31 · Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT04417062 · Dana-Farber Cancer Institute
2020-11-24 – 2026-12-01 · Osteosarcoma, Osteosarcoma Recurrent
What this study did
NCT05061134 · AstraZeneca
2022-08-11 – 2026-11-02 · Melanoma
What this study did
NCT03330847 · AstraZeneca
2018-03-07 – 2026-10-09 · Metastatic Triple Negative Breast Cancer
What this study did
NCT03334617 · AstraZeneca
2017-12-18 – 2026-09-11 · Non-Small Cell Lung Cancer
What this study did
NCT04065269 · Institute of Cancer Research, United Kingdom
2019-11-27 – 2026-08 · Gynaecological Cancers
What this study did
NCT04298008 · Seoul National University Hospital
2020-06-25 – 2025-12-31 · Bile Duct Cancer, Chemotherapy Effect
What this study did
NCT03462342 · University of Pennsylvania
2018-03-09 – 2025-07-21 · High Grade Serous Carcinoma
What this study did
NCT04564027 · AstraZeneca
2020-12-01 – 2025-02-18 · Advanced Solid Tumours
What this study did
NCT03833440 · Assistance Publique Hopitaux De Marseille
2019-10-08 – 2025-02 · Non-small Cell Lung Cancer
What this study did
NCT04298021 · Seoul National University Hospital
2020-06-25 – 2024-12-31 · Bile Duct Cancer, Chemotherapy Effect
What this study did
NCT03801369 · Gordon Mills, MD, PhD
2018-12-12 – 2024-12-23 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT02937818 · AstraZeneca
2016-11-28 – 2023-11-27 · Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
What this study did
NCT03182634 · Institute of Cancer Research, United Kingdom
2016-12-15 – 2023-11 · Advanced Breast Cancer
What this study did
NCT04361825 · Se-Hoon Lee
2020-06-17 – 2023-10-25 · Small Cell Lung Cancer
What this study did
NCT03428607 · Samsung Medical Center
2018-10-17 – 2021-01-15 · SCLC
What this study did
NCT02576444 · Joseph Paul Eder
2015-11 – 2019-11-18 · Cancer
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02813135 · Gustave Roussy, Cancer Campus, Grand Paris
2016-08-03 – 2031-02 · Pediatric Cancer
What this study did
Phase 1 (15)
Other / comorbidity
NCT04550104 · University of Leeds
2021-03-17 – 2028-03 · Non Small Cell Lung Cancer
What this study did
NCT05514132 · AstraZeneca
2022-09-23 – 2027-03-31 · Advanced Solid Tumours
What this study did
NCT04704661 · National Cancer Institute (NCI)
2021-08-09 – 2027-03-31 · Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
What this study did
NCT03770429 · Massachusetts General Hospital
2019-08-05 – 2026-12-31 · Leukemia, Myelodysplastic Syndrome
What this study did
NCT02264678 · AstraZeneca
2014-10-31 – 2026-12-30 · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
What this study did
NCT03328273 · Acerta Pharma BV
2018-01-31 – 2026-08-26 · Chronic Lymphocytic Leukemia
What this study did
NCT02223923 · Royal Marsden NHS Foundation Trust
2014-07 – 2025-12-30 · Solid Tumour Refractory to Conventional Treatment
What this study did
NCT06929260 · AstraZeneca
2025-05-21 – 2025-12-18 · Advanced Solid Tumours
What this study did
NCT06754761 · AstraZeneca
2025-09-22 – 2025-10-21 · Neoplasm
What this study did
NCT03669601 · CCTU- Cancer Theme
2019-10-15 – 2024-09-30 · Cancer
What this study did
NCT05469919 · AstraZeneca
2022-06-09 – 2024-03-12 · Advanced Solid Malignancies
What this study did
NCT02630199 · Samsung Medical Center
2015-12 – 2021-04-19 · Refractory Cancer
What this study did
NCT03527147 · Acerta Pharma BV
2018-06-19 – 2021-03-31 · NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
What this study did
NCT03022409 · AstraZeneca
2017-09-18 – 2021-01-20 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01955668 · AstraZeneca
2013-11 – 2013-12 · 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ceralasertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRDRecruiting
Est. primary completion 2026-12 · NCT03740893 · CT.gov ↗
What to watch
Phase 2Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03579316 · CT.gov ↗
What to watch
2027 (5)
January 2027 (1)
Phase 2Extensive Stage Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01 · NCT04699838 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma …Active not recruiting
Est. primary completion 2027-03-31 · NCT04704661 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Triple Negative Breast Cancer MetastaticRecruiting
Est. primary completion 2027-12 · NCT05582538 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Malignant MelanomaActive not recruiting
Est. primary completion 2027-12-01 · NCT03780608 · CT.gov ↗
What to watch
Phase 2Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2027-12-31 · NCT04090567 · CT.gov ↗
What to watch
2028 (4)
March 2028 (1)
Phase 2Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm …Active not recruiting
Est. primary completion 2028-03-31 · NCT03682289 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Non-Small Cell Lung CancerRecruitingDiscontinued in this indication
Est. primary completion 2028-06 · NCT06680050 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2028-06-30 · NCT06732401 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype …Recruiting
Est. primary completion 2028-12-31 · NCT06769126 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 December 2025Topline resultLATIFY Phase III did not meet primary endpoint of overall survival